Clinical research has demonstrated that high expression levels of CENPF results in poor prognosis in nasopharyngeal carcinoma (Cao et al., 2010), colorectal gastrointestinal stromal tumors (Chen et al., 2011), esophageal squamous cell carcinoma (Mi et al., 2013) and prostate cancer (Zhuo et al., 2015). Here, CENPF is linked to prostate cancer.